Omega-3 fatty acid ester compositions

A pharmaceutical composition for the treatment of at least one of the multiple risk factors for cardiovascular disease comprising from about 60% (wt/wt)—about 85% (wt/wt) of a mixed-fatty-acids composition in which, a) at least 80% by weight of the mixed-fatty-acids composition is comprised of Omega-3 fatty acids;

• b) at least 80% by weight of the total fatty acid content of the mixed-fatty-acids composition is comprised of a combination of (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 1:2 to 2:1, c) Omega-3 fatty acids other than EPA and DHA are present in an amount of at least 1.5% by weight of the total fatty acids;
• and d) at least one surface active agent is provided;
• wherein said at least one surface active agent comprises from about 15% to about 31% polysorbate 80 and from about 0.5% (wt/wt) to about 5% (wt/wt) of a block copolymer of polyethylene glycol and polypropylene glycol poloxamer having a chemical formula (HO(C2H4O)64(C3H6O)37(C2H4O)64H (Poloxamer 237);
• and wherein said composition, when administered to a human at equal dosage strengths, provides for substantially the same bioavailability when administered with or without food to said human in need of such administration.

A pharmaceutical composition comprising from about 60% (wt/wt)—about 85% (wt/wt) of a mixed-fatty-acids composition in which, a) at least 90% by weight of the composition is comprised of long chain, polyunsaturated, Omega-3 fatty acids;

• b) at least 80% by weight of the mixed fatty acids composition is comprised of a combination of (all-Z omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all-Z omega-3)-4, 7,10,13,16,19-docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 1:1 to 2:1, with the EPA constituting 40 to 60% by weight of the mixed fatty acids composition and the DHA constituting mixed fatty acids 25 to 45% by weight of the composition;
• c) at least 4.5% by weight of the mixed fatty acids composition is comprised of Omega-3 fatty acids other than EPA and DHA that have 18, 20, 21, or 22 carbon atoms;
• d) from 1 to 4% by weight of the mixed fatty acids composition is comprised of (all-Z omega-3)-6,9,12,15,18-heneicosapentaenoic acid;
• e) at least one surface active agent;
• and f) the composition is in oral dosage form and includes an effective amount of a pharmaceutically acceptable antioxidant;
• wherein said at least one surface active agent comprises from about 15% to about 31% polysorbate 80 and from about 0.5% (wt/wt) to about 5% (wt/wt) of a block copolymer of polyethylene glycol and polypropylene glycol having a chemical formula (HO(C2H4O)64(C3H6O)37(C2H4O)64H (Poloxamer 237);
• and wherein said composition, when administered to a human at equal dosage strengths, provides for substantially the same bioavailability when administered with or without food to said human in need of such administration.